参麦注射液的抗肿瘤作用研究

目的 研究参麦注射液体内外抗肿瘤作用。方法 以小鼠肉瘤S180、肝癌H22、Lewis肺癌实体瘤模型考察参麦注射液的体内抑瘤作用；通过MTT法考察参麦注射液体外对人宫颈癌HeLa细胞和人肝癌HepG 2细胞的增殖抑制作用。结果 参麦注射液在体内对小鼠肉瘤S180、肝癌H22、Lewis肺癌均有显著的抑制作用，且呈剂量相关性，中、高剂量抑瘤率可达35%以上；体外对人宫颈癌HeLa细胞和人肝癌HepG 2细胞亦有增殖抑制作用，且呈浓度–时间相关性，48 h的IC50值分别为0.36、0.72 g /mL，72 h的IC50值分别为0.21、0.29 g /mL。结论 参麦注射液体内外均有显著的抗肿瘤活性。

Antitumor activity of Shenmai Injection

Objective To investigate the antitumor effect of Shenmai Injection in vitro and in vivo. Methods Solid tumor models of mouse sarcoma S180, hepatoma H22, and Lewis lung carcinoma were used to study the antitumor effect of Shenmai Injection in vivo. MTT assay was used to examine its inhibitory effect on the proliferation of HeLa cell and HepG 2 cells. Results Shenmai Injection showed obviously inhibitory effect on the growth of S180, H22, and Lewis in tumor-bearing mice in a dose-dependent manner, and inhibitory rates in mid- and high-dose groups were over 35%. Shenmai Injection also inhibited the proliferation of HeLa cells and HepG 2 cells in vitro, showing a concentration-time correlation. The IC50 values of 48 h were 0.36 and 0.72 g/mL and the IC50 values of 72 h were 0.21 and 0.29 g/mL. Conclusion Shenmai Injection has remarkable antitumor activity both in vitro and in vivo.